Evidence map›Paper›PMID 12119061›Full record

ArticleBMC cell biology2002

A p130Cas tyrosine phosphorylated substrate domain decoy disrupts v-crk signaling.

Kathrin Kirsch, Margaret Kensinger, Hidesaburo Hanafusa, Avery August

Open access · goldAbstract read
In one paragraph

Article in BMC cell biology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. A truncated phosphorylated p130Cas substrate domain is sufficient to drive breast cancer growth and metastasis formation in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  4. Article
  5. Antimicrobial peptides: versatile biological properties.International journal of peptides · 2013
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Kathrin KirschLaboratory of Molecular Oncology, The Rockefeller University, NY, NY 10021, USA. kirschk@bu.edu
Margaret Kensinger
Hidesaburo Hanafusa
Avery August
Rockefeller University · USMolecular Oncology (United States) · USPennsylvania State University · US

Funding

CELL TRANSFORMATION BY RETROVIRUSR35CA044356 · NCI · ROCKEFELLER UNIVERSITY · PI HANAFUSA, HIDESABURO · 1987 to 1999
–
NCI NIH HHS CA44356
6 · The paper itself

Abstract

backgroundThe adaptor protein p130Cas (Cas) has been shown to be involved in different cellular processes including cell adhesion, migration and transformation. This protein has a substrate domain with up to 15 tyrosines that are potential kinase substrates, able to serve as docking sites for proteins with SH2 or PTB domains. Cas interacts with focal adhesion plaques and is phosphorylated by the tyrosine kinases FAK and Src. A number of effector molecules have been shown to interact with Cas and play a role in its function, including c-crk and v-crk, two adaptor proteins involved in intracellular signaling. Cas function is dependent on tyrosine phosphorylation of its substrate domain, suggesting that tyrosine phosphorylation of Cas in part regulates its control of adhesion and migration. To determine whether the substrate domain alone when tyrosine phosphorylated could signal, we have constructed a chimeric Cas molecule that is phosphorylated independently of upstream signals.

resultsWe found that a tyrosine phosphorylated Cas substrate domain acts as a dominant negative mutant by blocking Cas-mediated signaling events, including JNK activation by the oncogene v-crk in transient and stable lines and v-crk transformation. This block was the result of competition for binding partners as the chimera competed for binding to endogenous c-crk and exogenously expressed v-crk.

conclusionOur approach suggests a novel method to study adaptor proteins that require phosphorylation, and indicates that mere tyrosine phosphorylation of the substrate domain of Cas is not sufficient for its function.

Indexed as

ProteinsBinding, CompetitiveOncogene Protein v-crkPhosphoproteinsPhosphorylationPhosphotransferasesProtein Structure, SecondaryRecombinant ProteinsRetinoblastoma-Like Protein p130Retinoblastoma ProteinRetroviridae Proteins, OncogenicSignal TransductionTyrosineOncogene Protein v-crkPhosphoproteinsPhosphotransferasesProteinsRecombinant ProteinsRetinoblastoma-Like Protein p130Retinoblastoma ProteinRetroviridae Proteins, OncogenicTyrosine

Identifiers

PMID12119061
PMCPMC117778
OpenAlexW2166490896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.